This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zevalin

Spectrum Pharmaceuticals, Inc.

Drug Names(s): Yttrium-90 Ibritumomab Tiuxetan

Description: Zevalin is a radioactive version of IDEC's successful monoclonal antibody therapeutic Rituxan. Like Rituxan it binds to CD20 present on non-Hodgkin lymphoma cells. By carrying yttrium-90 to the target, it is better able to kill target cells. However, the drug has limitations in terms of ease of administration and toxicity issues. Zevalin is the first radioactive monoclonal antibody conjugate to receive FDA approval.

During development, Zevalin was competing with Bexxar, a similar radioactive antibody being developed for non-Hodgkin lymphoma treatment, to be the first approved radioactive therapeutic monoclonal antibody. Although Bexxar approval was initially anticipated ahead of Zevalin, Bexxar was held up and finally rejected by the FDA. Since Corixa has convinced the FDA to reconsider Bexxar, it yet still has a chance to directly compete with Zevalin.

Deal Structure: Drug revenue splits are BioMedTracker estimates. Spectrum stopped reporting U.S. revenue and started reporting WorldWide revenue in the second quarter of 2012.

IDEC and Schering
IDEC has used the resources it gained by developing Rituxan with Genentech to develop Zevalin on its own. IDEC retains all U.S. rights to market Zevalin, and has partnered with Schering for distribution in other world markets.

Bayer and Schering
In 2006, Bayer acquired Schering AG.

Cell Therapeutics and Biogen Idec
In August 2007, Cell Therapeutics (CTI) acquired Zevalin. Under the terms of the agreement, CTI will assume control of U.S. marketing, sales, and development of Zevalin. Upon closing, CTI has agreed to pay Biogen Idec $10 million in cash up front, up to an additional $20 million in milestone payments when the product receives approval for a first-line indication in NHL, and royalties on sales. CTI has also agreed to share the cost of certain clinical...See full deal structure in Biomedtracker

Partners: Bayer AG Biogen, Inc. CASI Pharmaceuticals, Inc. Mundipharma International Limited Les Laboratoires Servier


Zevalin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug